Abbott Receives CE Mark for Cologuard Plus in Europe
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Abbott's Cologuard Plus, a noninvasive DNA screening test for colorectal cancer, received the CE Mark under the European Union's In Vitro Diagnostic Medical Devices Regulation. This regulatory milestone allows Abbott to prepare for introducing the test in select European markets. The test detects both colorectal cancer and advanced precancerous lesions by analyzing DNA markers in stool.
From finanznachrichten.de
Why it matters
The CE Mark is a key regulatory step that allows Abbott to bring Cologuard Plus to consumers in Europe. Introduction into select European markets could increase sales and revenue for Abbott.
Market growth is anticipated in Eastern Europe for Abbott Laboratories as of July 21, 2025.
From finanznachrichten.de
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- EuropeSpeculative
Europe might see increased demand for diagnostic testing services as Abbott prepares to introduce Cologuard Plus.